GlassScriptPhysician profile
David W Malka
NPI 1235176322
$6,606.39
in general payments reported to CMS, 2019-2025
50 companies · $1,527 in 2025
The $1,527 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $698 · 2020: $315 · 2021: $609 · 2022: $948 · 2023: $1,059 · 2024: $1,450 · 2025: $1,527.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,036.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,036.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $867.07 | 2020-2025 | |
| Ucb, INC. | $556.69 | 2019-2025 | Briviact, Nayzilam |
| Teva Pharmaceuticals USA, INC. | $395.11 | 2019-2025 | Austedo Xr, Austedo Xr, Austedo |
| Neurocrine Biosciences, INC. | $377.53 | 2022-2025 | Ingrezza, Ongentys |
| Eisai INC. | $374.02 | 2020-2025 | |
| Genentech USA, INC. | $315.65 | 2019-2025 | Ocrevus, Ocrevus Zunovo, Enspryng |
| Amgen INC. | $265.77 | 2019-2025 | Uplizna |
| Supernus Pharmaceuticals, INC. | $250.76 | 2019-2020 | |
| Pfizer INC. | $233.25 | 2023-2025 | |
| Csl Behring | $211.79 | 2022-2025 | Hizentra |
| Argenx US, INC. | $206.15 | 2022-2025 | Vyvgart Hytrulo, Vyvgart |
| Tanabe Pharma America, INC. | $190.65 | 2023-2025 | Radicava |
| Sunovion Pharmaceuticals INC. | $169.31 | 2019-2021 | |
| Acadia Pharmaceuticals INC | $154.91 | 2023-2025 | Nuplazid |
| Lilly USA, LLC | $150.90 | 2021-2025 | Amyvid, Kisunla, Emgality |
Show all 50 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Malka listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.